Serotonin and brain function: a tale of two receptors
File(s)0269881117725915.pdf (867.65 KB)
Published version
Author(s)
Carhart-Harris, RL
Nutt, D
Type
Journal Article
Abstract
Previous attempts to identify a unified theory of brain serotonin function have largely failed to achieve consensus. In this present synthesis, we integrate previous perspectives with new and older data to create a novel bipartite model centred on the view that serotonin neurotransmission enhances two distinct adaptive responses to adversity, mediated in large part by its two most prevalent and researched brain receptors: the 5-HT1A and 5-HT2A receptors. We propose that passive coping (i.e. tolerating a source of stress) is mediated by postsynaptic 5-HT1AR signalling and characterised by stress moderation. Conversely, we argue that active coping (i.e. actively addressing a source of stress) is mediated by 5-HT2AR signalling and characterised by enhanced plasticity (defined as capacity for change). We propose that 5-HT1AR-mediated stress moderation may be the brain’s default response to adversity but that an improved ability to change one’s situation and/or relationship to it via 5-HT2AR-mediated plasticity may also be important – and increasingly so as the level of adversity reaches a critical point. We propose that the 5HT1AR pathway is enhanced by conventional 5-HT reuptake blocking antidepressants such as the selective serotonin reuptake inhibitors (SSRIs), whereas the 5-HT2AR pathway is enhanced by 5-HT2AR-agonist psychedelics. This bipartite model purports to explain how different drugs (SSRIs and psychedelics) that modulate the serotonergic system in different ways, can achieve complementary adaptive and potentially therapeutic outcomes.
Date Issued
2017-08-31
Date Acceptance
2017-08-31
Citation
Journal of Psychopharmacology, 2017, 31 (9), pp.1091-1120
ISSN
1461-7285
Publisher
SAGE Publications
Start Page
1091
End Page
1120
Journal / Book Title
Journal of Psychopharmacology
Volume
31
Issue
9
Copyright Statement
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Subjects
Depression
psychedelics
serotonin
11 Medical And Health Sciences
17 Psychology And Cognitive Sciences
Psychiatry
Publication Status
Published
Date Publish Online
2017-08-31